ARTICLE | Company News
Aphton, Receptor BioLogix deal
August 7, 2006 7:00 AM UTC
Receptor BioLogix acquired APHTQ's Insegia (G17DT) cancer vaccine in a Chapter 11 bankruptcy sale. Receptor BioLogix said it expects to pay no more than $1 million for the product and related assets. ...